Radiation-guided Drug Delivery to Mouse Models of Lung Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2010 Aug 31

PMID 20802016

Citations 17

Authors

Ghazal Hariri

Heping Yan

Hailun Wang

Zhaozhong Han

Dennis E Hallahan

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to achieve improved cancer-specific delivery and bioavailability of radiation-sensitizing chemotherapy using radiation-guided drug delivery.

Experimental Design: Phage display technology was used to isolate a recombinant peptide (HVGGSSV) that binds to a radiation-inducible receptor in irradiated tumors. This peptide was used to target nab-paclitaxel to irradiated tumors, achieving tumor-specificity and enhanced bioavailability of paclitaxel.

Results: Optical imaging studies showed that HVGGSSV-guided nab-paclitaxel selectively targeted irradiated tumors and showed 1.48 ± 1.66 photons/s/cm(2)/sr greater radiance compared with SGVSGHV-nab-paclitaxel, and 1.49 ± 1.36 photons/s/cm(2)/sr greater than nab-paclitaxel alone (P < 0.05). Biodistribution studies showed >5-fold increase in paclitaxel levels within irradiated tumors in HVGGSSV-nab-paclitaxel-treated groups as compared with either nab-paclitaxel or SGVSGHV-nab-paclitaxel at 72 hours. Both Lewis lung carcinoma and H460 lung carcinoma murine models showed significant tumor growth delay for HVGGSSV-nab-paclitaxel as compared with nab-paclitaxel, SGVSGHV-nab-paclitaxel,and saline controls. HVGGSSV-nab-paclitaxel treatment induced a significantly greater loss in vasculature in irradiated tumors compared with unirradiated tumors, nab-paclitaxel, SGVSGHV-nab-paclitaxel, and untreated controls.

Conclusions: HVGGSSV-nab-paclitaxel was found to bind specifically to the tax-interacting protein-1 (TIP-1) receptor expressed in irradiated tumors, enhance bioavailability of paclitaxel, and significantly increase tumor growth delay as compared with controls in mouse models of lung cancer. Here we show that targeting nab-paclitaxel to radiation-inducible TIP-1 results in increased tumor-specific drug delivery and enhanced biological efficacy in the treatment of cancer.

Citing Articles

A comparative analysis of sequence composition in different lots of a phage display peptide library during amplification.

Sinkjaer A, Sloth A, Andersen A, Jensen M, Bakhshinejad B, Kjaer A Virol J. 2025; 22(1):24.

PMID: 39893369 PMC: 11786364. DOI: 10.1186/s12985-024-02600-x.

Stimuli-Responsive Boron-Based Materials in Drug Delivery.

Das B, Chokkalingam P, Masilamani P, Shukla S, Das S Int J Mol Sci. 2023; 24(3).

PMID: 36769081 PMC: 9917063. DOI: 10.3390/ijms24032757.

Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.

Lewis C, Singh A, Hsu F, Thotala D, Hallahan D, Kapoor V Clin Cancer Res. 2021; 27(11):3224-3233.

PMID: 34074654 PMC: 9167454. DOI: 10.1158/1078-0432.CCR-20-1725.

Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.

DuRoss A, Landry M, Thomas Jr C, Neufeld M, Sun C Cancer Lett. 2020; 500:208-219.

PMID: 33232787 PMC: 9392493. DOI: 10.1016/j.canlet.2020.11.021.

Enhancing Radiotherapeutic Effect With Nanoparticle-Mediated Radiosensitizer Delivery Guided By Focused Gamma Rays In Lewis Lung Carcinoma-Bearing Mouse Brain Tumor Models.

Lim S, Li C, Jeong Y, Jang W, Choi J, Jung S Int J Nanomedicine. 2020; 14:8861-8874.

PMID: 32009784 PMC: 6859088. DOI: 10.2147/IJN.S227894.

References

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Gardner E, Dahut W, Figg W . Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 862(1-2):213-8. PMC: 2259285. DOI: 10.1016/j.jchromb.2007.12.013. View

Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz T, Milas L . 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res. 2007; 13(6):1868-74. DOI: 10.1158/1078-0432.CCR-06-2534. View

Belani C, Choy H, Bonomi P, Scott C, Travis P, Haluschak J . Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005; 23(25):5883-91. DOI: 10.1200/JCO.2005.55.405. View

Milenic D, Brechbiel M . Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther. 2004; 3(4):361-70. DOI: 10.4161/cbt.3.4.790. View

Geng L, Osusky K, Konjeti S, Fu A, Hallahan D . Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J Control Release. 2004; 99(3):369-81. DOI: 10.1016/j.jconrel.2004.07.024. View

Lee T, Lin C, Kuo S, Chang D, Wu H . Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res. 2007; 67(22):10958-65. DOI: 10.1158/0008-5472.CAN-07-2233. View

Damascelli B, Patelli G, Lanocita R, Di Tolla G, Frigerio L, Marchiano A . A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol. 2003; 181(1):253-60. DOI: 10.2214/ajr.181.1.1810253. View

Tai W, Mahato R, Cheng K . The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010; 146(3):264-75. PMC: 2918695. DOI: 10.1016/j.jconrel.2010.04.009. View

10.

Minshall R, Tiruppathi C, Vogel S, Niles W, Gilchrist A, Hamm H . Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol. 2000; 150(5):1057-70. PMC: 2175246. DOI: 10.1083/jcb.150.5.1057. View

11.

Hong J, Lee I, Kwak Y, Park Y, Sung H, Kwon I . Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther. 2007; 6(12 Pt 1):3239-47. DOI: 10.1158/1535-7163.MCT-07-0261. View

12.

Hallahan D, Geng L, Qu S, Scarfone C, Giorgio T, Donnelly E . Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell. 2003; 3(1):63-74. DOI: 10.1016/s1535-6108(02)00238-6. View

13.

Hawkins M, Soon-Shiong P, Desai N . Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008; 60(8):876-85. DOI: 10.1016/j.addr.2007.08.044. View

14.

Hallahan D, Qu S, Geng L, Cmelak A, Chakravarthy A, Martin W . Radiation-mediated control of drug delivery. Am J Clin Oncol. 2001; 24(5):473-80. DOI: 10.1097/00000421-200110000-00012. View

15.

Fournel P, Robinet G, Thomas P, Souquet P, Lena H, Vergnenegre A . Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01.... J Clin Oncol. 2005; 23(25):5910-7. DOI: 10.1200/JCO.2005.03.070. View

16.

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

17.

Pasqualini R, Ruoslahti E . Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380(6572):364-6. DOI: 10.1038/380364a0. View

18.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

19.

Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P . Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006; 17(8):1263-8. DOI: 10.1093/annonc/mdl104. View

20.

Vogel S, Minshall R, Pilipovic M, Tiruppathi C, Malik A . Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol. 2001; 281(6):L1512-22. DOI: 10.1152/ajplung.2001.281.6.L1512. View